Combined Detection Of Tumor Markers In The Diagnosis And Treatment Of Lung Cancer To Determine The Clinical Significance

Objective: Detect Serum carcinoembryonic antigen (carcinoembryonicantigen, CEA), cytokeratin 19 fragment antigen (CytokeratinFragmentAntigen21-l, CYFRA21-l), neuron-specific enolase (neuron-speeifieenolase, NSE), carbohydrate antigen -125 (Carbohydrate antigen-125,CA125)and carbohydrate antigen -153 (Carbohydrate antigen-153,CA153), to investigate the diagnosis and treatment of lung cancer to determine the clinical significance.methods:Collection of the First Affiliated Hospital of Dalian Medical University between 2009 and 2010 series of tumor markers are recorded in hospitalized patients, (1) 100 cases of lung cancer, (2) 60 patients with benign lung disease group, (3) 60 healthy people. Electricity were detected by chemiluminescence immunoassay in serum CEA, CYFRA21-l, NSE, CA125, CA153 levels. And lung cancer group of 45 patients with non-small cell lung cancer patients before and after operation serum CEA, CYFRA21-1, NSE, CA125, CA153 levels. Measured values of each group test of significance by analysis of variance, comparison between groups using t test, compared with the rate of X2 test, with Pearson rank correlation to determine the four markers the correlation between any two.Results:1.Lung cancer patients with a variety of tumor markers were significantly higher than those of benign lung disease and healthy control patients, the difference was statistically significant (P<0.05), benign lung disease group compared with the control group differences in their content not statistically significant (P>0.05).2.Between different pathological types of lung cancer tumor markers CEA, CYFRA21-1, NSE, CA125, CA153 levels were significantly different. CEA-positive diagnosis of lung cancer when the highest rate (82.1%), CA125, CA153, followed by squamous cell carcinoma CYFRA21-l-positive rate was the highest (73.0%), NSE-positive small cell lung cancer group, the highest rate (57.1%); diagnosis of pulmonary gland cancer when the highest specificity for CA125 (89.1%), CEA, followed by (79.8%), NSE in small cell lung cancer higher specificity (84.8%), CYFRA21-1对squamous higher specificity (84.9%) .3.Tumor markers combined detection sensitivity and accuracy than the individual tests were significantly improved, the difference was statistically significant (P <0.05), but specificity decreased.4.Pearson rank correlation with the four markers to determine the correlation between each confirmed the CEA, NSE, CYFRA21-1 and CA125 was no correlation between (P> 0.05), is independent of tumor markers in lung cancer can be combined detection.5.The serum CEA, CYFRA21-1, NSE, CA125, CA153 levels were decreased than those before surgery in the non-recurrence group,but increased or not changed in the recurrence group(P>0.05).Conclusion:1.Serum concentrations of CEA, CYFRA21-1, NSE, CA125 and CA153 are helpful in diagnosis of lung cancer.2.CEA, CA125, CA153 all the best tumor marker in adenocarcinoma ,CYFRA21-1 is the best tumor marker in squamous carcinoma ,NSE is the best tumor marker in small cell lung cancer.3.The sensitivity and accuracy of the combination of serum several tumor markers is higher than that of one marker in the early diagnosis of lung cancer.4.Dynamic observation of preoperative and postoperative serum CEA, CYFRA21-1, NSE, CA125, CA153 levels in the evaluation of surgery have better clinical reference value.